We originally posted on this last October (on our LinkedIn page, here) and now that the final numbers are in for 2019 we thought it would be good to revisit the topic.

‍

‍

With over 90 FDA warning letters issued throughout 2019, its critical to get quality control correct throughout the entire #pharma process, starting with #manufacturing and continuing along with the research, development and testing processes.

If the foundation isn’t solid to begin with, everything you build on top is useless. Do you agree?

Being successfully GMP, GLP, GCP certified and FDA audited multiple times, and with over 20-years experience of supporting the entire pharma cycle from start to finish, why not let QUINTA-ANALYTICA be your partner to success?

Get in touch with us today and let’s discuss your solution.

Additional News

  • 17 December 2025

    PF 2026: Thank You from Quinta-Analytica

    In 2025, Quinta-Analytica continued to turn complex development challenges into tangible progress. Our PF 2026 message looks back at key milestones and thanks the partners, clients, and teams who made them possible.

  • 15 December 2025

    IVBE for locally acting drugs: insights from Conscio Science Day in Munich

    Can bioequivalence for locally acting drugs be demonstrated without a single subject in a clinical trial? Yes, if your in vitro bioequivalence (IVBE) toolkit is set up in the right way.

  • 20 November 2025

    Webinar: Streamlined Evidence Strategies for Biosimilars: Analytics, PK and Immunogenicity in focus

    On behalf of Conscio Group, we are pleased to invite you to the upcoming free educational webinar from biosimilar series.

ALL POSTS